Trial reportESC heart failure2018
Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
Trial report in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2023Pooled it
- Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials.Frontiers in medicine · 2021Pooled it
- Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.European heart journal. Cardiovascular pharmacotherapy · 2018Guideline
- Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.ESC heart failure · 2018Trial
- Article
- Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.Clinical journal of the American Society of Nephrology : CJASN · 2024Review
- Assessment and management of heart failure in patients with chronic kidney disease.Heart failure reviews · 2024Review
- Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.ESC heart failure · 2022Article
- An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum.European journal of heart failure · 2022Article
- Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022Review
- Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.European journal of heart failure · 2022Article
- Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program.Drugs - real world outcomes · 2021Article
- Management of Heart Failure Patient with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2021Review
- The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction.ESC heart failure · 2021Article
- Review
- Pharmacodynamic effects of the KPhysiological reports · 2020Article
- Use of potassium-binder patiromer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report.European heart journal. Case reports · 2020Article
- Reappraisal on pharmacological and mechanical treatments of heart failure.Cardiovascular diabetology · 2020Review
- Narrative Review of Incremental Hemodialysis.Kidney international reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHyperkalaemia risk precludes optimal renin-angiotensin-aldosterone system inhibitor use in patients with heart failure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium-free, non-absorbed potassium (K METHODS AND
resultsThis open-label 8-week study enrolled 63 patients with CKD, serum K
conclusionsIn this open-label study, patiromer 16.8 g/day followed by individualized titration maintained serum K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.